癌症会对 Tayebat 体系产生反应；患有恶性肿瘤的患者应该现在就开始执行该体系（把饮食作为癌症治疗）。
原始表述
زي ما انا اكتشفت ان السرطان هيستجيب لي شغلي اه هيستجيب لي شغلي طبعا
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
癌症会对 Tayebat 体系产生反应；患有恶性肿瘤的患者应该现在就开始执行该体系（把饮食作为癌症治疗）。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- السرطان ١ (打开来源)
- 发布日期
- 2025年1月26日
- 时间戳
- 0:44:36 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; spelling errors of the machine transcript are kept verbatim; wording may deviate from the spoken words.
- 涉及人群
Cancer patients
- Elawady 设定的地域限制
none found
来源版本存在差异
ايوه طبعا يمشي على النظام اللي عنده ورم خبيث ده يمشي على النظام من دلوقتي
خفف سرطانات خفف
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr.D Clinics - Diaa Al Awady is live! مقدمة عن الدهون ⧸ الغشاء الخلوي (打开来源)
- 发布日期
- 2025年4月9日
- 时间戳
- 无（转录文本不含时间信息）
تنبيه: لا يُعد هذا دليلاً لعلاج السرطان. المرضى تحت إشراف فريق أورام.
- 来源状态
- 第三方网站（非官方）
- 归属
- Third-party site (unofficial)
- 出处
- https://mytayibat.com/mytayibat-cancer
ايه النظام المناسب للقضاء على سرطان المخ يا باشا هو نظام واحد انا ما اخترعتش 600 نظام [أصوات شخير] يعني انا ما اخترعتش 600 نظام هو نظام واحد هو نظام الطيبات اا ونظام الطيبات هو مش نظام بمعنى اصح هو تكنيك وانا اسف كلمه تكنيك دي لو
Asked which system is suitable for eliminating brain cancer, he answered that there is only one system, the Tayebat system, which is a technique based on forbidding some foods and allowing others.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا تصليح مفاهيم (打开来源)
- 发布日期
- 2026年3月31日
- 时间戳
- 0:13:42 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
科学评估
错误 – 该说法与可靠证据相矛盾。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
The diet treats or controls cancer.
2. 哪些内容可证实是正确的？
Nutrition matters during cancer (e.g., preventing malnutrition) and healthy weight lowers some cancer risks; using a diet alongside treatment is not by itself harmful (I-CHM-04 shows risk was mediated by refusal).
3. 哪些内容是错误或夸大的？
No evidence that the Tayebat diet shrinks or cures cancer; testimonies in the videos are unverifiable and often involve prior surgery or chemotherapy. Alternative-only management of curable cancers was associated with HR 2.50 for death (I-CHM-03). In patients who were eventually treated, each 4-week delay within the studied range of about 4-16 weeks was associated with 6-13% higher mortality for many indications (observational; I-CHM-07); the longer delays of trying a diet first were not studied, and the authors warn against extrapolating beyond 16 weeks.
4. 哪些内容仍不明确？
Long-term outcomes of the patients presented in the videos.
5. 哪些研究支持该说法？
None for diet as treatment. In a randomised trial, a low-fat diet added to conventional treatment after breast cancer surgery was associated with somewhat fewer relapses (9.8% vs 12.4%; HR 0.76, borderline; I-CAN-131). A small randomised trial of a supervised ketogenic diet added to chemotherapy for metastatic pancreatic cancer showed non-significant trends toward longer survival (I-CAN-125); ketogenic diets alongside standard care improved some metabolic and symptom measures (I-CAN-103); CAM combined with full treatment was not associated with higher mortality in GI cancers (I-CAN-102). None of this supports replacing or delaying treatment. The registry 'CAM' studies capture non-medical alternative treatment rather than supportive complementary care (I-CAN-128).
6. 哪些研究与该说法相矛盾？
I-CHM-03, I-CHM-04, I-CHM-07, I-CAN-101 (breast cancer, CAM alone AHR 3.67), I-CAN-102 (GI cancers, CAM alone aHR 1.86), I-CAN-129 (refusal of colon cancer surgery, HR 3.41), I-CAN-104 (ketogenic-diet RCTs: insufficient evidence), I-CAN-105 (ASCO: diet evidence very limited), I-CAN-106 (NCI: no diet proven to control cancer).
7. 对德国和欧洲而言情况如何？
Not region-specific; the evidence on the harms of replacing or delaying cancer treatment (I-CHM-03, I-CHM-04, I-CHM-07) applies equally in Germany and Europe.
8. 关于埃及的已知情况是什么？
Not region-specific; the same risks apply. The videos address mainly Egyptian and Arab patients, so the claim is practically relevant there.
9. 合理的实际结论是什么？
可以与肿瘤团队讨论把饮食作为支持性照护，但绝不能把它作为替代治疗。
评估详情
- 证据确定性的依据
No clinical study of the Tayebat system in cancer exists (none found); indirect but consistent evidence shows excess mortality when diet/alternative approaches replace treatment. Certainty is moderate because the evidence on this specific diet is indirect.
- 来源质量
Machine transcript; third-party site disagrees.
- 地区可推广性
High.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: In people with a malignant tumour, does adopting the Tayebat diet (or any diet) instead of, or before, standard oncological treatment control the cancer, and how does replacing or delaying standard treatment affect survival?
研究问题详解 (PICO)
- 人群
- Patients with malignant tumours
- 干预或暴露
- Tayebat system / diet-based or other alternative management used instead of or before standard treatment
- 对照
- Standard oncological treatment (surgery, chemotherapy, radiotherapy, endocrine, targeted, immunotherapy)
- 地域范围
- universal biology
- 结局指标
- Overall survival
- Tumour response / cancer control
- Treatment delay
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
A low-fat diet alongside breast cancer treatment may reduce relapse
Chlebowski RT et al.. J Natl Cancer Inst 2006 · PMID 17179478 · DOI 10.1093/jnci/djj494 随机对照试验已核查摘要新增WINS randomised trial: a low-fat diet added to conventional treatment after breast cancer surgery.
- 实际结果
- Relapse 9.8% vs 12.4%; HR 0.76 (0.60-0.98); log-rank P=.077, Cox P=.034
- 方法学质量
- moderate (large RCT; interim, open-label, borderline)
- 相关性
- indirect: diet as an adjunct to treatment, a different diet
- 局限
- Borderline significance; not a replacement of treatment.
Ketogenic diet added to chemotherapy for pancreatic cancer: early trial
Randomised phase II trial: a medically supervised ketogenic diet added to chemotherapy for metastatic pancreatic cancer.
- 实际结果
- Median PFS 8.5 vs 6.2 months, HR 0.53 (0.21-1.37); OS 13.7 vs 10.2 months, HR 0.58 (0.25-1.37); not statistically significant
- 方法学质量
- moderate design, low precision (n=32, one-sided alpha 0.20, commercial COI)
- 相关性
- indirect: diet added to chemotherapy, not instead of it; different diet
- 局限
- Unconfirmed trend; small.
Ketogenic diets in cancer patients: some metabolic benefits
Meta-analysis of ketogenic diets in cancer patients (mostly alongside standard care) found better metabolic and some symptom outcomes.
- 实际结果
- Reduced fat mass, insulin, glucose, fatigue and insomnia; no survival or tumour outcomes in abstract.
- 方法学质量
- low-moderate (surrogate outcomes, small studies)
- 相关性
- indirect: a different diet, used as an adjunct, not a replacement
- 局限
- No evidence on tumour control or survival; not the Tayebat diet.
哪些证据不支持该说法？
Breast cancer patients who used only alternative medicine died more often
Ayoade OF et al.. JAMA Netw Open 2026 · PMID 41770560 · DOI 10.1001/jamanetworkopen.2026.0337 队列研究已核查全文新增In 2.16 million women with breast cancer (NCDB 2011-2021), CAM used instead of standard therapy was associated with much higher mortality; partial replacement also raised mortality.
- 实际结果
- CAM alone AHR 3.67 (3.03-4.44); combination AHR 1.45 (1.22-1.72); unadjusted 5-y OS 60.1% vs 85.4%
- 方法学质量
- moderate (large registry, adjusted, full text read)
- 相关性
- direct: replacing treatment with non-medical approaches
- 局限
- Observational; CAM undocumented in many; not diet-specific.
Refusing colon cancer surgery linked to much shorter survival
Kaltenmeier C et al.. Am J Surg 2020 · PMID 32680623 · DOI 10.1016/j.amjsurg.2020.04.022 队列研究已核查摘要新增NCDB colon cancer: refusing recommended surgery (coded independently of CAM).
- 实际结果
- Median survival 6.8 vs 24 months; HR 3.41
- 方法学质量
- moderate (very large registry)
- 相关性
- direct for not starting curative treatment
- 局限
- Confounding by frailty; reasons for refusal unknown.
Each month of delay in cancer treatment raises the risk of death
Meta-analysis of treatment delay: each 4-week delay associated with higher mortality.
- 实际结果
- 6-13% higher mortality per 4-week delay for many indications (as recorded)
- 方法学质量
- moderate
- 相关性
- direct for 'start the diet first'
- 局限
- Observational; delays beyond 16 weeks not studied.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Diet is not a treatment for cancer; replacing or delaying standard treatment with a diet or other alternatives is associated with markedly higher mortality.
为什么有些研究权重更大
Survival data on replacement or refusal of treatment (I-CHM-03, I-CAN-101, I-CAN-102, I-CHM-04, I-CAN-129) weigh most because they address the decision the claim recommends; they come from one registry (NCDB) and partly overlap, so they count as one replicated source; a 2026 critique (I-CAN-128) shows that the NCDB variable captures registry-coded non-medical alternative treatment (not supportive complementary care) and that some analytic details are unclear, which limits the size estimates but not the direction, and it explicitly affirms the concern about replacing treatment. Randomised trials of diets added to standard treatment (I-CAN-131 low-fat diet, borderline fewer relapses; I-CAN-125 ketogenic diet, unconfirmed trend) are the fair 'supporting' side: nutrition may help alongside treatment, which is the opposite of the claim's practical advice. RCT-level diet evidence (I-CAN-104) and the ASCO guideline (I-CAN-105) show no diet has proven cancer control. Ketogenic-diet data (I-CAN-103) concern adjunct use and surrogate outcomes.
因果关系是否已确立？ 很可能 Randomising patients to forgo curative treatment would be unethical; large, consistent adjusted hazard ratios across cancers, a dose-like gradient (no treatment ~ CAM alone > partial > full treatment) and the known efficacy of standard treatment from RCTs (I-CHM-01, I-CHM-05) make a causal harm probable.
仍存在的不确定性
No study of the Tayebat system itself; NCDB misclassification; effect of diets used strictly as adjuncts.
合理的结论
This claim is false: no diet, including the Tayebat system, has been shown to treat cancer, and using it instead of or before standard treatment is associated with substantially higher mortality.
为什么研究结果看起来互相矛盾？
Apparent conflict between ketogenic-diet meta-analyses (I-CAN-103 positive, I-CAN-104 largely null) reflects different inclusion criteria (non-randomised vs RCT-only) and surrogate endpoints; neither addresses replacement of treatment. NCDB studies agree (Johnson 2018, Ayoade 2026, Ekenze 2026) but share one database. Ekenze found no excess mortality with CAM combined with treatment in GI cancers, whereas Ayoade found excess mortality in breast cancer, apparently because combination users skipped radiation and endocrine therapy - both support the same conclusion: harm arises from forgoing treatment. Jeitler 2026 (I-CAN-128) criticises the NCDB studies for construct validity, immortal-time handling and missing tumour-biology adjustment; this weakens precise effect sizes and any inference about supportive complementary care, but not the conclusion about replacing treatment. The positive trend in I-CAN-125 concerns a diet added to chemotherapy and therefore does not conflict with the harm of replacing treatment.
这是否取决于国家？
- 一般生物学效应
- Universal human biology; applies in Egypt, Germany and elsewhere.
- 饮食习惯
- The Tayebat diet has not been studied in cancer anywhere; Egyptian/Arab patients are the main audience of the videos.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Not relevant.
- 实际监测数据
- No Egyptian data on alternative-medicine use and survival were found.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- CI log-symmetry of AHRs; unadjusted absolute survival difference; stage confounding – AHR CIs symmetric (ratio 0.99); unadjusted 5-y OS difference 25.3 points, partly confounded by stage (31.8% vs 18.1% stage III-IV); adjusted absolute risks not reported, NNH not derivable. 已重新计算
- CI log-symmetry; size of exposed group – Symmetric; CAM-only 0.013% of cohort -> imprecise estimate. 已重新计算
- CI symmetry; absolute risk; robustness – HR CI symmetric; crude relapse 9.8% vs 12.4%, ARR 2.5 points, NNT about 39 over ~5 years; log-rank P=.077 vs Cox P=.034 -> fragile. 已重新计算
- CI symmetry; one-sided vs two-sided testing – Symmetric; two-sided p about 0.18/0.21 from the CIs; one-sided alpha 0.20 screening design -> no confirmed effect. 已重新计算
- CI log-symmetry – Reported CI 3.12-3.60 asymmetric around 3.41 (ratio 0.61); possible reporting/rounding error, not resolvable from the abstract; Medicaid OR upper limit 43.77 implausible (not used). 已重新计算
- Independence of NCDB cohorts – Johnson, Ayoade and Ekenze share the NCDB with 3-4 overlapping diagnosis years -> counted as one replicated data source. 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Overall survival when diet/alternative medicine replaces standard treatment
- 起始等级
- 低（观察性研究）
- 降级理由
- indirectness (no Tayebat-specific data; NCDB category is registry-coded non-medical treatment, I-CAN-128)
- risk of bias (residual confounding; unclear immortal-time handling)
- 升级理由
- large effect (HR 2.5-3.7)
- dose-response-like gradient (full > partial > no treatment)
- consistency across cancers and periods
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- US National Cancer Institute: Complementary and Alternative Medicine (CAM) (2024) · 原始文献
Alternative medicine is used instead of standard treatment, e.g. a special diet instead of oncology drugs; no special diet, food, vitamin or mineral is proven to slow or cure cancer; patients should tell their doctor about CAM use. - ASCO: Exercise, Diet, and Weight Management During Cancer Treatment (PMID 35576506) (2022) · 原始文献
Exercise recommended during curative treatment; neutropenic diets not recommended; evidence for other dietary and weight-loss interventions during treatment very limited (abstract). - ESPEN: ESPEN guidelines on nutrition in cancer patients (I-INTA-09, PMID 27637832) (2017) · 原始文献
Screen all cancer patients for malnutrition and meet energy and protein needs, except at end of life (as recorded for I-INTA-09; abstract). - WHO: Cancer - fact sheet (2026) · 原始文献
About 38% of cancers can be prevented by avoiding risk factors (tobacco, alcohol, unhealthy diet, inactivity, air pollution); about 10% are attributable to infections; many cancers can be cured if detected early and treated effectively. - ESMO: Statement on alternative medicine replacing cancer treatment 无法获取；内容未采用
- NCCN: NCCN Guidelines (require login) · 原始文献 无法获取；内容未采用
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | (diet OR "dietary intervention" OR "ketogenic") AND (cancer OR tumor) AND (survival OR "tumor response" OR remission) AND (PUB_TYPE:"Systematic Review" OR PUB_TYPE:"Meta-Analysis" OR TITLE:"meta-analysis") AND PUB_YEAR:[2018 TO 2026] | 支持性证据 | 3756 | |
| Europe PMC | 2026年10月26日 | TITLE:(ketogenic) AND TITLE:(cancer OR tumor OR glioma OR glioblastoma) AND (randomized OR randomised) AND PUB_YEAR:[2015 TO 2026] | 支持性证据 | 114 | |
| Europe PMC | 2026年10月26日 | ("alternative medicine" OR "alternative therapy" OR "refusal of conventional" OR "refused treatment" OR "treatment refusal" OR "declined treatment") AND (cancer) AND (survival OR mortality) AND PUB_YEAR:[2017 TO 2026] | 反对性证据 | 13958 | |
| Europe PMC | 2026年10月26日 | ("fasting mimicking" OR "fasting-mimicking") AND (chemotherapy) AND (randomized OR randomised OR trial) | 支持性证据 | 489 | |
| Europe PMC | 2026年10月26日 | TITLE:"Exercise, Diet, and Weight Management During Cancer Treatment" | 指南 | 2 | |
| Europe PMC | 2026年10月26日 | (TITLE:"ESPEN" AND TITLE:"cancer") AND (guideline OR guidelines) | 指南 | 8 | |
| Europe PMC | 2026年10月26日 | (Tayebat OR Tayibat OR Elawady OR "El-Awady diet" OR "Al-Awady") | 双向 | 377 | |
| Europe PMC | 2026年10月26日 | ("complementary and alternative medicine" OR "herbal medicine" OR "traditional medicine") AND (cancer) AND (Egypt OR Egyptian OR Arab OR "Middle East") | 双向 | 5921 | |
| PubMed | 2026年10月26日 | (diet therapy[MeSH Terms] OR "dietary intervention"[tiab]) AND neoplasms[MeSH Terms] AND (survival[tiab] OR "tumor response"[tiab]) AND randomized controlled trial[pt] | 支持性证据 | 36 | |
| PubMed | 2026年10月26日 | ("diet alone"[tiab] OR "dietary treatment"[tiab] OR "nutritional therapy"[tiab]) AND (cancer[tiab]) AND (remission[tiab] OR regression[tiab]) AND (cohort[tiab] OR trial[tiab]) | 支持性证据 | 10 | |
| PubMed | 2026年10月26日 | ("alternative medicine"[tiab] OR "alternative therapy"[tiab]) AND (cancer[tiab]) AND (survival[tiab] OR mortality[tiab]) AND ("National Cancer Database"[tiab] OR cohort[tiab]) | 反对性证据 | 45 | |
| PubMed | 2026年10月26日 | ("refusal"[tiab] OR "declined"[tiab]) AND ("conventional treatment"[tiab] OR "standard treatment"[tiab] OR "chemotherapy"[tiab]) AND cancer[tiab] AND survival[tiab] | 反对性证据 | 774 | |
| Web (WebFetch, NCI cancer.gov) | 2026年10月26日 | https://www.cancer.gov/about-cancer/treatment/cam | 指南 | 1 | |
| Web (WebSearch) | 2026年10月26日 | ESMO guideline complementary alternative medicine replace conventional cancer treatment statement | 指南 | 9 |
待解决的问题
Outcomes of patients shown in the videos; Egyptian data on alternative-medicine use in cancer.
核查深度如何？
14 项相关研究：3 项核查了全文（其中 1 项进行了结构化偏倚风险评估），11 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 错误 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 错误 (中)
Unchanged. New 2026 registry studies (I-CAN-101, I-CAN-102) replicate the earlier finding in larger and more recent cohorts, and guidelines (I-CAN-105, I-CAN-106) confirm that no diet is proven to control cancer. Certainty stays moderate because all data on the specific diet are indirect and the cohorts share one registry.
新来源: I-CAN-101 I-CAN-102 I-CAN-103 I-CAN-104 I-CAN-105 I-CAN-106 I-CAN-118 I-CAN-125 I-CAN-128 I-CAN-129 I-CAN-131
通俗解释
Diaa 医生说，癌症“会对”他的体系“产生反应”，患有恶性肿瘤的患者应立即开始执行。没有任何研究表明这种饮食能治疗癌症。研究显示，用替代疗法取代标准治疗的人死亡更多。良好的饮食可以为患者提供支持，但只能与正规的癌症治疗一起进行。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (10)
-
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145队列研究独立交叉核查已核查摘要★ 关键研究Risk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.
Alternative-only approach worse
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare AM-only vs conventional treatment.
- 研究是如何开展的？
Matched registry cohort.
- 研究了多少人、动物或样本？
840 matched patients.
- 实际发现了什么？
HR 2.50 for death.
- 观察到的效应有多大？
HR 5.68 breast cancer.
- 研究结果对日常生活意味着什么？
Replacing cancer treatment with alternatives is dangerous.
- 该研究有哪些局限？
Observational.
- 它对 Elawady 的具体说法说明了什么？
Contradicts refusing therapy.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Effects of complementary approaches used alongside treatment.
-
Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death
Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487队列研究独立交叉核查已核查摘要★ 关键研究Users of complementary medicine refused chemotherapy or radiotherapy far more often and had about twice the risk of death.
Risk mediated by refusing therapy
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Study CM and survival.
- 研究是如何开展的？
Registry cohort.
- 研究了多少人、动物或样本？
258 vs 1,032.
- 实际发现了什么？
HR 2.08; explained by refusal.
- 观察到的效应有多大？
5-y OS 82.2% vs 86.6%.
- 研究结果对日常生活意味着什么？
Diet or other approaches alongside treatment are not the problem; replacing treatment is.
- 该研究有哪些局限？
Observational.
- 它对 Elawady 的具体说法说明了什么？
Contradicts refusal advice.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Causal effect of any single CM.
-
Each month of delay in cancer treatment raises the risk of death
Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087Meta分析独立交叉核查全文，含结构化偏倚风险评估★ 关键研究For example, every 4-week delay of breast surgery was linked to 8% higher mortality.
Trying diet first delays treatment
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Quantify harm from delay.
- 研究是如何开展的？
Meta-analysis.
- 研究了多少人、动物或样本？
1.27 million patients.
- 实际发现了什么？
Higher mortality with delay.
- 观察到的效应有多大？
HR 1.06-1.08 per 4 weeks (surgery).
- 研究结果对日常生活意味着什么？
Do not postpone recommended treatment.
- 该研究有哪些局限？
Observational, mostly US registry data; valid only for delays of about 4-16 weeks; not suitable for predicting an individual's risk.
- 它对 Elawady 的具体说法说明了什么？
Safety.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
The effect of delays longer than 16 weeks or of refusing treatment altogether; the effect for every cancer type; proof of causation.
-
Breast cancer patients who used only alternative medicine died more often
Ayoade OF et al.. JAMA Netw Open 2026 · PMID 41770560 · DOI 10.1001/jamanetworkopen.2026.0337队列研究独立交叉核查已核查全文★ 关键研究Using alternative medicine instead of standard treatment was linked to a 3.7-fold higher risk of death; skipping parts of treatment also raised risk.
CAM alone AHR 3.67 vs standard therapy
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Compare survival with alternative medicine vs standard treatment in breast cancer.
- 研究是如何开展的？
US national registry cohort, adjusted Cox models.
- 研究了多少人、动物或样本？
2.16 million women; 273 used alternative medicine only.
- 实际发现了什么？
Higher death risk with alternative medicine alone, similar to no treatment.
- 观察到的效应有多大？
AHR 3.67 (3.03-4.44); 5-year survival 60.1% vs 85.4% (unadjusted).
- 研究结果对日常生活意味着什么？
Replacing breast cancer treatment with alternatives is dangerous.
- 该研究有哪些局限？
Observational; registry may miss much alternative-medicine use.
- 它对 Elawady 的具体说法说明了什么？
Contradicts the advice to treat cancer with a diet.
- 研究结果是否适用于德国和欧洲？
Moderate (US data; same principle in Europe).
- 从该研究中明确不能得出什么结论？
Effects of complementary methods used alongside full standard treatment.
-
Gastrointestinal cancer: alternative medicine alone linked to more deaths
Ekenze SO et al.. J Gastrointest Surg 2026 · PMID 42607749 · DOI 10.1016/j.gassur.2026.102552队列研究独立交叉核查已核查摘要★ 关键研究Patients who used only alternative medicine had an 86% higher risk of death; those who combined it with standard care did not.
CAM alone aHR 1.86; combined use aHR 1.00
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Survival with alternative medicine in GI cancers.
- 研究是如何开展的？
US registry cohort.
- 研究了多少人、动物或样本？
1.5 million patients; 197 alternative-only.
- 实际发现了什么？
Alternative-only use linked to higher mortality.
- 观察到的效应有多大？
aHR 1.86 (1.37-2.51).
- 研究结果对日常生活意味着什么？
Do not replace cancer treatment with alternatives.
- 该研究有哪些局限？
Small group; observational; overlaps with other NCDB studies.
- 它对 Elawady 的具体说法说明了什么？
Contradicts diet as cancer treatment; supports use only alongside treatment.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Whether any specific diet helps.
-
Ketogenic diet trials in cancer: little proven benefit
Salido-Bueno B et al.. Nutr Bull 2024 · PMID 38923748 · DOI 10.1111/nbu.12693Meta分析独立交叉核查已核查摘要In 7 small randomised trials, a ketogenic diet lowered blood glucose but did not clearly improve other cancer-related measures.
No convincing effect of a ketogenic diet in RCTs
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Assess ketogenic diet effects in cancer RCTs.
- 研究是如何开展的？
Meta-analysis of RCTs.
- 研究了多少人、动物或样本？
8 RCTs of 4-16 weeks.
- 实际发现了什么？
Only glucose fell.
- 观察到的效应有多大？
Not quantified in abstract.
- 研究结果对日常生活意味着什么？
No diet has been shown to treat cancer.
- 该研究有哪些局限？
Small, short trials.
- 它对 Elawady 的具体说法说明了什么？
Contradicts diet-as-treatment claims.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Long-term effects.
-
US cancer doctors' guideline: exercise helps, diet evidence weak
Ligibel JA et al.. J Clin Oncol 2022 · PMID 35576506 · DOI 10.1200/JCO.22.00687指南 / 立场声明独立交叉核查已核查摘要★ 关键研究ASCO found that exercise helps during cancer treatment but that evidence for specific diets is very limited.
Diet evidence for cancer control very limited
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide exercise, diet and weight during cancer treatment.
- 研究是如何开展的？
Systematic review plus expert panel.
- 研究了多少人、动物或样本？
52 reviews and 23 RCTs.
- 实际发现了什么？
Exercise helps; no diet shown to control cancer.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Diet can support, not replace, treatment.
- 该研究有哪些局限？
Few diet trials.
- 它对 Elawady 的具体说法说明了什么？
Contradicts diet as cancer cure.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Absence of effect for all diets.
-
US National Cancer Institute: no diet is proven to control cancer
National Cancer Institute. cancer.gov (NCI, US National Institutes of Health) 2024指南 / 立场声明独立交叉核查已核查摘要★ 关键研究The NCI states that no special diet has been proven to slow or cure cancer.
No special diet proven to control cancer
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Inform patients about CAM.
- 研究是如何开展的？
Agency summary.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
No diet proven to control cancer.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Talk to the oncology team before using any diet against cancer.
- 该研究有哪些局限？
Summary page.
- 它对 Elawady 的具体说法说明了什么？
Contradicts the claim.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Detailed evidence grading.
-
WHO: many cancers are preventable and curable
World Health Organization. who.int 2026指南 / 立场声明独立交叉核查已核查摘要About 38% of cancers can be prevented by avoiding risk factors, and many can be cured with early, effective treatment.
Many cancers curable when treated effectively
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Summarise cancer facts.
- 研究是如何开展的？
Agency fact sheet.
- 研究了多少人、动物或样本？
Global.
- 实际发现了什么？
Preventable external causes; curable with treatment.
- 观察到的效应有多大？
38% preventable.
- 研究结果对日常生活意味着什么？
Avoid tobacco and alcohol; get treated early.
- 该研究有哪些局限？
Summary.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'not caused by external agents'.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Detailed estimates.
-
Refusing colon cancer surgery linked to much shorter survival
Kaltenmeier C et al.. Am J Surg 2020 · PMID 32680623 · DOI 10.1016/j.amjsurg.2020.04.022队列研究独立交叉核查已核查摘要Patients who refused recommended surgery lived a median of 6.8 months vs 24 months.
Refusing curative surgery: HR 3.41; median survival 6.8 vs 24 months
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Effects of refusing surgery.
- 研究是如何开展的？
Registry cohort.
- 研究了多少人、动物或样本？
924,290 patients.
- 实际发现了什么？
Much worse survival after refusal.
- 观察到的效应有多大？
HR 3.41.
- 研究结果对日常生活意味着什么？
Do not delay or refuse curative treatment.
- 该研究有哪些局限？
Observational.
- 它对 Elawady 的具体说法说明了什么？
Contradicts the claim.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Reasons for refusal.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (4)
-
Ketogenic diets in cancer patients: some metabolic benefits
Zhang M et al.. Front Nutr 2025 · PMID 40756563 · DOI 10.3389/fnut.2025.1535921Meta分析独立交叉核查已核查摘要Ketogenic diets lowered body fat, insulin and glucose and improved some symptoms; survival was not shown to improve.
Diet changes metabolic/symptom outcomes alongside therapy; no survival evidence
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Effect of ketogenic diets in cancer patients.
- 研究是如何开展的？
Systematic review and meta-analysis.
- 研究了多少人、动物或样本？
Cancer patients in controlled studies.
- 实际发现了什么？
Better metabolic and some quality-of-life measures.
- 观察到的效应有多大？
Not quantified in abstract.
- 研究结果对日常生活意味着什么？
A diet can affect how patients feel and some blood values.
- 该研究有哪些局限？
Surrogate outcomes; small studies.
- 它对 Elawady 的具体说法说明了什么？
Does not show that a diet treats cancer.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
That any diet cures or controls cancer.
-
Ketogenic diet added to chemotherapy for pancreatic cancer: early trial
Jameson GS et al.. Cancer 2026 · PMID 41817106 · DOI 10.1002/cncr.70343随机对照试验独立交叉核查已核查摘要★ 关键研究In 32 patients, adding a supervised ketogenic diet to chemotherapy showed a trend toward longer survival that was not statistically confirmed.
Diet added to chemotherapy: non-significant trends; not tested as replacement
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test a ketogenic diet added to chemotherapy.
- 研究是如何开展的？
Randomised phase II trial.
- 研究了多少人、动物或样本？
32 patients.
- 实际发现了什么？
Trends toward longer PFS/OS.
- 观察到的效应有多大？
PFS HR 0.53 (0.21-1.37).
- 研究结果对日常生活意味着什么？
Diet research in cancer is about adding to treatment, not replacing it.
- 该研究有哪些局限？
Small; uncertain; COI.
- 它对 Elawady 的具体说法说明了什么？
Does not support diet instead of treatment.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Any proven survival benefit.
-
Critique: registry 'CAM' is really alternative treatment instead of standard care
Jeitler M et al.. Oncologist 2026 · PMID 42135607 · DOI 10.1093/oncolo/oyag187其他独立交叉核查已核查全文★ 关键研究Experts note that the US registry studies capture people who used non-medical alternatives as cancer treatment, not complementary therapies in general.
Methodological limits of NCDB CAM studies; affirms concern about treatment substitution
该研究是否支持这一具体说法？ 不明确 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Critique NCDB CAM studies.
- 研究是如何开展的？
Commentary.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Exposure narrow; some methods unclear.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
The warning applies to replacing treatment, not to supportive therapies.
- 该研究有哪些局限？
No new data.
- 它对 Elawady 的具体说法说明了什么？
Sharpens, does not weaken, the safety message.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Precise size of harm.
-
A low-fat diet alongside breast cancer treatment may reduce relapse
Chlebowski RT et al.. J Natl Cancer Inst 2006 · PMID 17179478 · DOI 10.1093/jnci/djj494随机对照试验独立交叉核查已核查摘要★ 关键研究Women who cut dietary fat while receiving standard treatment had somewhat fewer relapses (9.8% vs 12.4%), but the result was borderline.
Diet as adjunct to conventional treatment: HR 0.76 for relapse (borderline)
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test low-fat diet after breast cancer surgery.
- 研究是如何开展的？
Randomised trial.
- 研究了多少人、动物或样本？
2,437 women.
- 实际发现了什么？
Fewer relapses with diet (borderline).
- 观察到的效应有多大？
HR 0.76 (0.60-0.98).
- 研究结果对日常生活意味着什么？
Diet may help alongside treatment, not instead of it.
- 该研究有哪些局限？
Interim; borderline.
- 它对 Elawady 的具体说法说明了什么？
Does not support diet as replacement.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
That any diet cures cancer.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Not region-specific; the evidence on the harms of replacing or delaying cancer treatment (I-CHM-03, I-CHM-04, I-CHM-07) applies equally in Germany and Europe.
埃及
Not region-specific; the same risks apply. The videos address mainly Egyptian and Arab patients, so the claim is practically relevant there.
在我的国家适用什么？
一般科学评估
错误 该说法错误：没有任何饮食（包括 Tayebat 体系）被证明能治疗癌症，而用它取代标准治疗与明显更高的死亡率相关。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
- Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.. Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
- Mortality due to cancer treatment delay: systematic review and meta-analysis.. Hanna TP et al.. BMJ 2020 · PMID 33148535 · DOI 10.1136/bmj.m4087
- Use of Complementary and Alternative Medicine in the Management of Breast Cancer.. Ayoade OF et al.. JAMA Netw Open 2026 · PMID 41770560 · DOI 10.1001/jamanetworkopen.2026.0337
- Complementary and alternative medicine use: impact on survival among patients with gastrointestinal cancers.. Ekenze SO et al.. J Gastrointest Surg 2026 · PMID 42607749 · DOI 10.1016/j.gassur.2026.102552
- Effects of ketogenic diets on cancer-related variables: A systematic review and meta-analysis of randomised controlled trials.. Salido-Bueno B et al.. Nutr Bull 2024 · PMID 38923748 · DOI 10.1111/nbu.12693
- Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.. Ligibel JA et al.. J Clin Oncol 2022 · PMID 35576506 · DOI 10.1200/JCO.22.00687
- Complementary and Alternative Medicine (CAM) for cancer - patient information page. National Cancer Institute. cancer.gov (NCI, US National Institutes of Health) 2024
- Cancer - WHO fact sheet. World Health Organization. who.int 2026
- Refusal of cancer-directed treatment by colon cancer patients: Risk factors and survival outcomes.. Kaltenmeier C et al.. Am J Surg 2020 · PMID 32680623 · DOI 10.1016/j.amjsurg.2020.04.022
- Impact of ketogenic diets on cancer patient outcomes: a systematic review and meta-analysis.. Zhang M et al.. Front Nutr 2025 · PMID 40756563 · DOI 10.3389/fnut.2025.1535921
- A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.. Jameson GS et al.. Cancer 2026 · PMID 41817106 · DOI 10.1002/cncr.70343
- When "CAM" is not CAM: Interpreting national cancer database analyses in breast cancer.. Jeitler M et al.. Oncologist 2026 · PMID 42135607 · DOI 10.1093/oncolo/oyag187
- Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.. Chlebowski RT et al.. J Natl Cancer Inst 2006 · PMID 17179478 · DOI 10.1093/jnci/djj494